Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...